CG
JSPR icon

Cutler Group’s Jasper Therapeutics JSPR Stock Holding History

Cutler Group’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4
Closed – – 2962
2023
Q4 		$0 Hold
4
– – ﹤0.01% 3978
2023
Q3 		$0 Buy
4
+1
+33% +$366 ﹤0.01% 4066
2023
Q2 		$1K Hold
3
– – ﹤0.01% 3321
2023
Q1 		$1K Buy
+3
New +$1.66K ﹤0.01% 3462

Other funds holding JSPR

Velan Capital Investment Management
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $8.36B AUM 14.46% 1-Year Est. Return
Qiming U.S. Ventures Management
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Avidity Partners Management
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Samsara BioCapital
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Sphera Funds Management
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Octagon Capital Advisors
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Cutler Group's JSPR Position: Q1 2024 in Review

Cutler Group sold out of Jasper Therapeutics (JSPR) in Q1 2024, closing a stake of 4 shares.

Cutler Group first reported a position in JSPR in Q1 2023 and held it in 4 quarters. The position peaked at $1K in Q2 2023. 59 funds tracked by Wall St. Rank hold JSPR as of Q1 2024.

  • Cutler Group reported no remaining Jasper Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 4 Jasper Therapeutics shares in Q1 2024.
  • Cutler Group first reported a position in Jasper Therapeutics in Q1 2023 and held it in 4 quarters.
  • Cutler Group's Jasper Therapeutics position peaked at $1K in Q2 2023.
  • 59 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.